Sygnature Discovery Unlocks Life-Changing Treatment Options with New Human Disease Modeling Platform
Sygnature Discovery has unveiled its humanized neuroinflammation in vitro platform, SCANME (SCreening for Anti-Neuroinflammation Molecular Entities), designed to scale up human disease modeling and push the boundaries of treatment for life-changing neuroinflammation related conditions such as Alzheimer’s disease.
Neurodegenerative diseases caused by neuroinflammation are a major global health issue, yet the drug development process is notoriously slow with high clinical failure rates exceeding 96%. For instance, the first drug targeting the amyloid hypothesis for Alzheimer’s was only approved in the US last year, after a 40-year R&D cycle.
To address these challenges, SCANME leverages human induced pluripotent stem cells (iPSCs), derived from somatic cells, to offer biologically relevant insights that increase confidence in clinical translation and help ‘humanize’ drug discovery.
SCANME provides a scalable, human-relevant disease model which produces robust and reproducible data, accelerating the path from compound discovery to clinical insights.
A standout feature of SCANME is its integration of High Content Imaging (HCI), which captures multiple parameters simultaneously during disease modeling, enriching biological understanding. Additionally, the platform’s flexibility and scalability offer a range of customizable options to suit various research needs.
Max Mirza, Vice President, Neuroscience Drug Discovery said: “Sygnature Discovery’s SCANME platform stands at the forefront of drug discovery by allowing researchers to scale up the application of specialized human iPSC-derived cells, particularly microglia, which are essential for neuroinflammation research.
“We are committed to continuous innovation and investing in the right technology to ensure that we remain ahead of the curve, bringing new possibilities and advancements to our broader neuroscience offering for customers.
“Our collaboration with Axol Bioscience, a leader in manufacturing functionally relevant human iPSC-derived cells, ensures that we provide the highest quality cells and technical support. This partnership combines unparalleled expertise and innovative approaches to deliver optimal research outcomes.
“Sygnature’s deep expertise in neuroscience research guarantees a detailed understanding of the field’s challenges and requirements. The SCANME platform boasts unmatched customization, advanced imaging, focused expertise, and scalability”.
About Sygnature Discovery
Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global pharma, biotech, and NFP organizations. Since 2011, Sygnature Discovery has delivered over 40 novel pre-clinical and 25 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.
Meet Sygnature Discovery at SfN’s Neuroscience 2024 conference in Chicago (Oct 5-9), booth #633
